Replies to post #29962 on Marker Therapeutics Inc (MRKR)

[KeithamdMIC]

After being informed that MRKR received Orphan status on one treatment in trial ongoing, the average increase in a stock that received Orphan FDA approval is a gain of 3.66 %. I think the one key advantage of Orphan Status is the FDA gives MRKR the 7 year protection against any generic competition in the marketplace. That is really the most significant protection we can have. Their are other financial openings also.

[pure profit]

So are you buying here? after this 13% haircut today? just wondering